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Background. Snail is a key regulator of epithelial-mesenchymal transition of tumor cells. Several studies have shown nuclear Snail
expression to be a negative prognostic factor in human cancer, where it is generally associated with more aggressive tumor behavior
and worse survival. Objectives and Methods. To further explore the role of Snail expression in breast cancer, we conducted a study
on a tissue microarray, encompassing 1043 breast cancer cases. Results. A total of 265 (25.4%) breast cancers were positive for Snail.
Snail expression was significantly associated with greater tumor size, higher tumor stage and grade, positive lymph node status, and
hormone receptor negative status and was differently expressed in the intrinsic subtypes of breast cancer, being the highest in the
basal-like subtype and the lowest in the luminal A subtype. In multivariate analysis, Snail proved to be an independent negative
prognostic factor for OS. In the intrinsic subtypes, Snail expression was a negative prognostic factor for OS in the luminal B HER2− ,
the luminal B HER2+ , and the basal-like subtype. Conclusions. This is the first study demonstrating that nuclear Snail expression is
an independent negative predictor of prognosis in breast cancer, thus suggesting that it may represent a potential therapeutic target.

1. Introduction
Snail, a zinc finger transcription factor, is a key regulator
of epithelial-mesenchymal transition (EMT) of epithelial
tumor cells [1]. It directly represses transcription of the cell
adhesion molecule E-cadherin while inducing transcription
of mesenchymal genes [2, 3]. EMT leads to a loss of epithelial
features and a gain of mesenchymal features and cell motility
and allows the tumor to progress to invasive cancer and metastatic disease [2, 4].
Snail messenger RNA (mRNA) expression has been
detected in breast cancer, gastric cancer, hepatocellular carcinomas, and ovarian carcinomas [2, 5–7]. However, since
Snail is subject to posttranslational modifications, mRNA
expression does not necessarily correlate with the amount
of active Snail protein [8]. Certain cell lines express both
Snail mRNA and cytoplasmic Snail but lack nuclear Snail [9].
Importantly, these cell lines show no detectable Snail activity,

suggesting that nuclear Snail expression is a better predictor
of Snail activity than analysis of Snail mRNA [8, 9].
Several studies have shown nuclear Snail expression to
be a negative prognostic factor in human cancer. Shin et al.
found that nuclear Snail expression is significantly associated with tumor progression, lymph node metastases, and
shorter survival in gastric carcinomas [10]. Similarly, nuclear
Snail expression is associated with higher tumor stage and
grade and constitutes an independent prognostic predictor
of recurrence-free survival and cancer-specific survival in
urothelial carcinoma [11] and is associated with aggressive
tumor behavior and worse OS in hepatocellular carcinoma
[12]. Blechschmidt et al. showed that nuclear Snail expression
in ovarian cancer metastases is associated with lower overall
survival [8].
In breast cancer, several immunohistochemical studies
have investigated the role of nuclear Snail expression [9, 13,
14]. Geradts et al. and Lundgren et al. found an association
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between Snail and higher tumor grade and proliferation rate
as well as an association between Snail and estrogen receptor
(ER) negativity [3, 14]. A recent study by ElMoneim and
Zaghloul showed that nuclear expression of Snail is associated
with higher tumor grade and greater tumor size and stage
as well as positive lymph node status in breast cancer [13].
The authors also confirmed an association between Snail
expression and progesterone receptor (PR) [15] and ER
negative breast cancer cases [13]. Looking at the impact of
Snail expression on prognosis in human breast cancer, some
studies found no significant correlation with survival [14],
while others report that nuclear Snail expression significantly
predicts poorer disease free survival in patients with positive
lymph node status, and ER− as well as PR− breast cancers [4].
Additionally, Snail has been shown to be required for tumor
growth and lymph node metastasis in a heterotransplanted
human breast cancer cell line [16].
To further explore the role of nuclear Snail expression in
human breast cancer, we conducted an immunohistochemical study on a breast cancer tissue microarray [17] encompassing a total of 1043 formalin fixed breast cancer cases with
detailed clinical annotation and outcomes data. The aim of
our study was to investigate the association between nuclear
Snail expression and other clinicopathological parameters in
breast cancer and to study the impact of Snail on prognosis.

2. Materials and Methods
2.1. Tissue Microarray. We used a TMA encompassing 1402
breast cancer tissue punches of formalin-fixed and paraffinembedded tumor samples collected from patients diagnosed
with primary breast cancer between 1985 and 2007 at the
Institute for Pathology, University of Basel, and the Viollier
Institute in Basel, Switzerland. Of these 1402 tissue punches,
a total of 1043 were evaluable for our study. The tissue samples
were brought into a TMA format as previously described [18].
Briefly, 0.6 mm tissue cylinders were punched out of donor
tumor tissue blocks and transferred into a recipient paraffin
block using a semiautomated tissue arrayer. Each TMA
contained a number of tumor punches ranging from 159 to
522. Histopathological data was obtained from the pathology
reports, and raw patient survival data was obtained from
the Cancer Registry of Basel or from the patient’s attending
physician. Retrieval of tissue and clinical data was performed
according to the regulations of the local institutional review
boards and data safety laws with specific regard to ethical
standards and patient confidentiality. The mean follow-up
time of the patients was 69.9 months (range 1 to 174 months),
and the median age was 63.1 years (range 27 to 101 years).
Demographic information of the patients can be found in
Table 1.
2.2. Immunohistochemistry. For immunohistochemical
staining, 4 𝜇m sections of the TMA blocks were incubated
overnight with the polyclonal anti-Snail antibody (Clone
RB1400, Abgent, San Diego, CA, USA) in a dilution of 1 : 100
after heat induced antigen retrieval with citrate buffer at pH 6.
Standard DAB technique (Dako EnVision+ System-labelled
Polymer Anti-rabbit followed by Liquid DAB+ Substrate
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Chromogen System) was employed for immunostaining.
Counterstaining was performed with hematoxylin solution.
The percentage of cells with a distinctive strong nuclear
staining was estimated (Figure 1). Snail expression was only
evaluated in tumor cells, and all cases with a nuclear Snail
expression of 5% of tumor cells were considered positive. Our
decision to set the threshold at ≥5% was based primarily on a
distribution analysis of the cases in this study. Since 42.6% of
cases with nuclear Snail expression were in the 5% and 10%
categories, we decided that a cutoff set at ≥5% represents the
most appropriate threshold. The staining intensity of ER, PR,
and human epidermal growth factor receptor 2 (HER2) was
scored as described previously [19].
2.3. Statistical Analysis. The distributions of patient and
clinical characteristics between Snail positive and negative
tumors were compared using Chi-square test, Wilcoxon rank
sum test, or two-sample 𝑡-test as appropriate. Overall survival
(OS) was defined as the time from the first operation to death
due to any cause. Survivors were censored at the date of last
contact. Survival curves by Snail status were estimated using
the Kaplan-Meier product-limit method and compared by
log-rank test. Univariate Cox proportional hazard models
were fit to identify factors significantly related to overall survival. To assess whether Snail was an independent predictor of
survival, a multivariate Cox model was constructed to adjust
other patient/clinical characteristics that were significant in
the univariate analyses. Two-way interaction terms between
Snail and other factors in the multivariate Cox model were
also assessed. All analyses were two-sided and significance
was set at a 𝑃 value of 0.05. Statistical analyses were performed using SAS (SAS Institutes, Cary, NC).

3. Results
Using a threshold of ≥5% of cancer cell nuclei staining
positive for Snail, a total of 265 (25.4%) of the 1043 evaluable
primary breast cancers were positive. Snail expression was
significantly associated with greater tumor size, higher tumor
stage and grade, positive lymph node status, higher Ki-67
expression and ER− and PR− status (Table 2), and histological
subtype, being the highest in the medullary subtype (71%)
and lowest in the cribriform subtype (9%) (data not shown).
Of note, there was a significant association between Snail
expression and ER− status (Snail expression 13.0% in ER+
cancers versus 64.4% in ER− cancers, 𝑃 value < 0.0001) as
well as PR− status (Snail expression 15.0% in PR+ cancers
versus 29.9% in PR− cancers, 𝑃 value < 0.0001) (Table 2). No
significant association between Snail expression and HER2
status was found (Table 2). In addition, Snail expression was
associated with the intrinsic subtypes of breast cancer, as
defined by the St. Gallen consensus conference. The breast
cancer intrinsic subtypes were originally defined by gene
expression profiling [20, 21] but can be approximated using
immunohistochemistry for ER, PR, Ki-67, and HER2 [22, 23].
These subtypes are known to have differing epidemiological
risk factors, prognosis, and response to therapy [23]. Snail
expression was the highest in the basal-like subtype (73.8%)
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(a)

(b)

Figure 1: Representative photographs of nuclear Snail expression in breast cancer with (a) invasive ductal carcinoma with nuclear Snail
staining. Magnification 400x. (b) Invasive ductal carcinoma negative for Snail staining. Magnification 400x.

Table 1: Basic demographic data for 1043 evaluable breast cancer cases.

Tumor stage
pT1
pT2
pT3
pT4
Lymph node involvement
pN0
pN1
pN2
Tumor grade
1
2
3
Histologic subtype
Invasive ductal
Invasive lobular
Mucinous
Apocrine
Cribriform
Papillary
Medullary
Other
Intrinsic subtype
Luminal A
(ER+ and/or PR+ , HER2− , Ki-67 < 14%)
Luminal B (HER2− )
ER+ and/or PR+ , HER2− , Ki-67 ≥ 14%)
Luminal B (HER2+ )
(ER+ and/or PR+ , HER2+ )
HER2 type (ER− or PR− , HER2+ )
Basal-like (ER− , PR− , HER2− )
Mean tumor size (mm) ± standard deviation (SD)
Mean age at diagnosis (years) ± standard deviation (SD)

Number (𝑛)

Percent (%)

307
544
71
121

29.4
52.2
6.8
11.6

555
398
87

53.4
38.3
8.3

254
439
350

24.4
42.1
33.5

735
152
30
11
33
15
31
35

70.5
14.6
2.9
1.1
3.2
1.4
3.0
3.3

176

16.9

507

48.7

120

11.4

79
160

7.6
15.4
31.5 ± 16.8
63.1 ± 13.7
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Table 2: Association between Snail expression and clinicopathological parameters.

Clinicopathologic parameter
Mean tumor size (mm) ± SD
Mean age at diagnosis (years) ± SD

Snail positive
35.1 ± 20.4
63.2 ± 14.9

𝑃 value
<0.0001
0.9164

Snail negative
27.9 ± 15.6
63.1 ± 13.3

(𝑛)
Tumor stage
pT1
pT2
pT3
pT4
Lymph node involvement
pN0
pN1
pN2
Tumor grade
1
2
3
Estrogen receptor
ER+
ER−
HER2
HER2+
HER2−
Ki67
Ki67+
Ki67−

<0.0001
47
128
20
70

15.3
23.5
28.2
57.8

260
416
51
51

84.7
76.5
71.8
42.2

115
103
47

20.7
25.9
54.0

440
295
40

79.3
74.1
46.0

28
59
178

11.0
13.4
50.9

226
380
172

89.0
86.6
49.1

102
163

13.0
64.4

685
90

87.0
35.6

59
206

29.6
24.4

140
638

70.4
75.6

229
35

28.5
15.0

574
198

71.5
85.0

<0.0001

<0.0001

<0.0001

0.1266

<0.0001

and the lowest in the luminal A subtype (11.9%, 𝑃 < 0.001)
(Table 3).
Studying the impact of Snail expression on survival, we
found that in univariate survival analyses, breast cancer cases
with positive Snail expression had a significantly worse OS
(hazard ratio (HR) = 2.843, 𝑃 < 0.001) (Table 4 and Figure 2).
In multivariate analysis, after adjusting for age, grade, tumor
size, lymph node status, and intrinsic subtype, Snail remained
an independent negative prognostic factor for OS (HR =
1.930, 𝑃 < 0.001) (Table 5). In subset univariate analyses of
the specific intrinsic subtypes, Snail expression proved to be
a negative prognostic factor for OS in the luminal B HER2−
type (HR = 3.674, 𝑃 < 0.0001), the luminal B HER2+
type (HR = 3.692, 𝑃 < 0.0001), and the basal-like subtype
(HR = 3.610, 𝑃 = 0.0006) (Table 4 and Figure 2). Of note, the
negative prognostic effect of Snail expression was independent of ER (Table 6), PR, and HER2 status (data not shown).

4. Discussion
In our study, we evaluated the nuclear expression of Snail
in a large cohort of functionally annotated primary breast
cancer specimens. We observed that Snail is expressed in
25.4% of primary breast cancers. This is practically identical
to the results of Geradts et al. as well as Lundgren et al., who
used the same scoring system as we did and found nuclear

Snail expression in 23.7% of their breast cancer specimens
(𝑛 = 58 and 𝑛 = 384, resp.) [3, 14]. Similarly, Becker et al.
reported 33% of breast cancers as being positive for nuclear
Snail staining [24]. Taking a cutoff of >10% nuclear Snail
expression in tumor cells, ElMoneim and Zaghloul found a
significantly higher Snail expression in breast cancers (40.9%,
𝑛 = 132) [13]. Other studies that have used a weighted
histoscore, multiplying the proportion of stained cells by the
intensity of staining, have also found significantly higher
nuclear Snail expression in breast cancer (42.6% and 54%,
resp.) [4, 13, 25]. Since all of the breast cancers in our
collective with nuclear Snail expression showed a strong
staining intensity, we assessed the percentage of positive
nuclei in each tumor but did not integrate staining intensity
into a combined score. Our decision to set the threshold at
≥5% was based primarily on a distribution analysis of the
cases in this study. Since 42.6% of cases with nuclear Snail
expression were in the 5% and 10% categories, we decided that
a cutoff set at ≥5% represents the most appropriate threshold.
The differences seen with some of the previously mentioned
studies could also be due to different antibodies used for the
immunohistochemical staining.
In accordance with previous reports of nuclear Snail
expression in human breast cancers, we found a significant
association between Snail and higher tumor grade and
proliferation rate as well as with greater tumor size and stage
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Figure 2: Kaplan-Meier survival curve for (a) overall survival depending on Snail expression (univariate analysis). (b)–(f) Kaplan-Meier
survival curve for overall survival depending on Snail expression for the intrinsic breast cancer subtype.
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Table 3: Association between Snail expression and breast cancer intrinsic subtype.

Intrinsic subtype
Luminal A
(ER+ and/or PR+ , HER2− , Ki-67 < 14%)
Luminal B (HER2-negative)
ER+ and/or PR+ , HER2− , Ki-67 ≥ 14%)
Luminal B (HER2-positive)
(ER+ and/or PR+ , HER2+ )
HER2 type (ER− , PR− , HER2+ )
Basal-like (ER− , PR− , HER2− )

(𝑛)

Snail positive
(%)

Snail negative
(𝑛)
(%)

21

11.9

155

88.1

67

13.2

440

86.8

20

16.7

100

83.3

39
118

49.4
73.7

40
42

50.6
26.3

𝑃 value

<0.0001

Table 4: Univariate analyses for all cases, by intrinsic subtype, for the effect of Snail expression on overall survival.
Snail expression, all cases
Snail positive
Snail expression, by intrinsic subtype
Luminal A
Luminal B (HER2− )
Luminal B (HER2+ )
HER2 type
Basal-like

Hazard ratio (95% CI)
1.702 (0.755–3.834)

𝑃 value
<0.0001

1.702 (0.755–3.834)
3.674 (2.637–5.119)
3.692 (1.971–6.915)
1.616 (0.843–3.101)
3.610 (1.728–7.541)

0.1994
<0.0001
<0.0001
0.1485
0.0006

[3, 13, 14]. In compliance with the notion that Snail expression
leads to a more mobile and aggressive cancer cell type, nuclear
Snail expression was also significantly associated with lymph
node metastases in our collective, a finding concordant with
the results of previous studies [3, 13, 14].
Furthermore, we could confirm the association between
nuclear Snail expression and ER− as well as PR− status
described in previous immunohistochemical studies [3, 13,
14] and by microarray analysis of primary human breast cancers [26]. The inverse association between Snail expression
and expression of ER has also been described for breast cancer
cell lines [26] and is in line with a current model depicting
transcriptional repression of Snail as a secondary biological
effect of the ER [27, 28]. Additionally, it has also been shown
that Snail is in turn able to directly downregulate ER [26].
Taken together, this data suggests a crucial role for the ER
in EMT-dependent tumor progression. A study by Lundgren
et al. reports that breast cancer patients with nuclear Snail
expression have a better response to tamoxifen [14], but the
underlying mechanism of this effect is yet to be elucidated.
Speculatively, tamoxifen might inhibit the function of Snail,
as described previously for the ER antagonist ICI [14]. This
in turn may lead to a less invasive tumor phenotype, since
EMT is reverted [14]. Interestingly, another study found that
acquisition of hormonal resistance in breast cancer correlates
with increase in Snail expression and activity while inhibition
of Snail partially restores the sensitivity of the resistant cancer
cells to tamoxifen [29]. Evidently, further studies including
large randomized clinical cohorts are needed to investigate
the role of Snail as a treatment predictive marker in breast
cancer.
In our collective, Snail expression was differently associated with the intrinsic breast cancer subtypes, being the

highest in the basal-like subtype and the lowest in the luminal
A subtype. In the only study to date looking at nuclear
Snail expression in breast cancer subtypes, Geradts et al.
found nuclear Snail protein in 75% of triple-negative breast
cancers [3], which is almost identical to our findings in the
basal-like intrinsic subtype (73.8%). Of note, the St. Gallen
consensus conference uses the triple-negative phenotype as
an approximation for basal-like breast cancer [23].
Our results show that nuclear Snail expression is an
independent prognostic factor for worse OS in primary breast
cancers. This is in contrast with a previous study by Logullo
et al. where the authors found no significant correlation
between Snail expression and survival. In their study, the
authors, however, analyzed only cytoplasmic Snail expression, and their collective of invasive breast cancers was quite
small (𝑛 = 55) [30]. In an independent study, Yuen et al.
found no impact of nuclear Snail expression on survival in
a collective of 115 breast cancers when looking at all cases but
found that nuclear Snail expression significantly predicted
poorer disease-free survival in patients with positive lymph
node status and ER− as well as PR− breast cancers [4].
Contrastingly, van Nes et al. found an association between
nuclear Snail expression and a decreased relapse-free period
in patients with ER+ breast cancers [25]. Of note, in our collective of 1043 breast cancer patients, the negative prognostic
effect of Snail expression was independent of ER status. Since
Snail represents an important transcription factor for EMT
in carcinomas, thus increasing cell motility and allowing the
tumor to metastasize, and it is very feasible that nuclear
expression of Snail is associated with a worse prognosis in
breast cancer, as it has been shown in various other human
cancers [10–12].
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Table 5: Multivariate analysis for the effect of clinicopathologic parameters and Snail expression on overall survival.
Clinicopathologic parameter
Age (per 1 year )
Tumor stage
pT1 (reference)
pT2
pT3
pT4
Lymph node involvement
pN1 (reference)
pN1
pN2
Tumor grade
BRE grade 1 (reference)
2
3
Snail expression, all cases
Snail positive
Snail expression, by intrinsic subtype
Luminal A (reference)
Luminal B (HER2− )
Luminal B (HER2+ )
Her2
Basal-like

Table 6: Effect of Snail on overall survival by ER status.
Effects of Snail expression

Hazard ratio (95% CI)

0.2391

Interaction with ER status
+

ER
ER−

𝑃 value

3.334 (2.530–4.394)
2.443 (1.575–3.789)

When looking at the different intrinsic breast cancer
subtypes, we are the first to show that nuclear Snail expression
is a negative prognostic factor for OS in the luminal B HER2−
type, the luminal B HER2+ type, and the basal like subtype.
Due to its important role in the epithelial-mesenchymal
transformation of tumor cells and its correlation with tumor
malignancy, Snail is an attractive target for the development
of blocking pharmaceutical agents [31]. By blocking Snail,
cell migration and invasion, and, consequently, metastasis of
tumor cells are diminished, thus improving the clinical outcome. With the Schiff base complex Co(III)-Ebox, a highly
selective inhibitor that prevents Snail from binding to its
DNA target has recently been identified [32] and has proven
to be a potent inhibitor of Snail-mediated transcriptional
repression in breast cancer cells [31]. It is thus feasible that
this selective inhibitor could be used to therapeutically target
Snail and other zinc-finger transcription factors such as Slug
in human cancers.

5. Conclusions
Our study is the largest TMA study to date to evaluate the role
of nuclear Snail expression in breast cancer and is the first to

Hazard ratio (95% CI)
1.037 (1.029–1.046)

𝑃 value
<0.0001

1
1.392 (1.042–1.859)
1.620 (1.047–2.508)
1.619 (1.103–2.377)

0.0251
0.0303
0.0140

1
1.446 (1.147–1.822)
2.603 (1.852–3.658)

0.0018
<0.0001

1
1.593 (1.161–2.186)
2.123 (1.510–2.986)

0.0039
<0.0001

1.930 (1.476–2.524)

<0.0001

1
1.012 (0.721–1.414)
1.206 (0.788–1.844)
0.999 (0.618–1.614)
1.258 (0.819–1.934)

0.9458
0.3884
0.9958
0.2951

demonstrate that nuclear Snail expression is an independent
predictor of prognosis in breast cancer and is differently
expressed in the intrinsic breast cancer subtypes. Our data
suggests that Snail represents a potential target in human
breast cancer. Of note, targeted inactivation of Snail with the
Schiff base complex Co(III)-Ebox has recently been reported
in breast cancer cells [31]. Routine staining for Snail in breast
cancer could thus be used to identify patients eligible for
targeted therapy but could also identify those patients with
a more aggressive course of disease. Additional studies to
define the functional role of Snail in human breast cancer and
assess treatment options are, however, needed.
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